Cita APA

Salamero García, O., Willekens, C., Pérez-Simón, J. A., Pigneux, A., Récher, C., Carpio Segura, C. C., . . . Bosch, F. (2020). First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

Citación estilo Chicago

Salamero García, Olga, Christophe Willekens, José Antonio Pérez-Simón, Arnaud Pigneux, Christian Récher, Cecilia Carmen Carpio Segura, Pau Montesinos, y Francesc Bosch. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. 2020.

Cita MLA

Salamero García, Olga, et al. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. 2020.